Immuno-oncology Treatment Devices and Drugs Industry - Regional Synopsis
North America Market Analysis
The North America immuno-oncology treatment devices and drugs market is predicted to capture the largest share of 48.8% over the forecasted timeframe. The region’s dominance is primarily attributable to the heightened Medicare expansion covering 86% of drugs and the improved healthcare expenditure. The efforts from countries such as the U.S. and Canada stand out at the forefront for this upliftment. Besides, the checkpoint inhibitors draw 62% of the U.S. medical spending, reflecting the increased adoption. Meanwhile, the 2023 Inflation Reduction Act extended its support to lower the expenses to USD 2,000 in a year, boosting patient accessibility.
Canada complements the regional expansion of North America's immuno-oncology treatment devices and drugs market, driven by the improved outcomes in terms of AI-based diagnostics. Market in the country rises at 9.7% CAGR owing to the enhanced provincial healthcare investments, which is USD 1.2 billion, and public funding is covering 76% of drugs, persisting in a positive support. To reduce reliance on imports, Health Canada in 2025 launched CAR-T production, thereby contributing to the strong propagation in the sector.
Europe Market Statistics
Europe in the immuno-oncology treatment devices and drugs market is poised to hold the second largest share of 30.3%, rising at a CAGR of 10.2%, with the strong presence of key market players such as Germany and the U.K. In this regard, the EU Cancer Mission allocated a significant amount of €4.2 billion for research and development in terms of immunotherapy from 2021, offering 13% annual growth in immune-oncology adoption. Besides, on the regulatory front, the EU Health Data Space is currently integrating real-world evidence to optimize the prescription of I-O, which appreciably reduces delay by 6 months.
There is a huge opportunity for the immuno-oncology treatment devices and drugs market in the U.K., which holds 28.4% of the share in the European market. The region benefits from a huge patient pool; As per the NHS report in 2023, 26,000 patients in the country received immune oncology therapies, which reflects the accelerated demand. Besides, the budget allocation also plays a crucial role in the industry upliftment, with 10% of the NHS cancer budget being spent on immune oncology, which is £1.3 billion. Therefore, the existence of these factors as growth drivers remarkably sets standards for expansion.
